Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5395659 | 0.99 | GSK3B (0.41) | GSK3BEIF2AK2TRPA1CDK2MKNK1 | |
| SCHEMBL5378772 | 0.99 | GSK3B (0.41) | GSK3BEIF2AK2TRPA1CDK2MKNK1 | |
| SCHEMBL5389042 | 0.95 | MKNK1 (0.43) | GSK3BTRPA1CDK2MKNK1 | |
| SCHEMBL5389843 | 0.95 | MKNK1 (0.46) | GSK3BTRPA1CDK2MKNK1 | |
| SCHEMBL5383851 | 0.93 | GSK3B (0.41) | GSK3BEIF2AK2TRPA1CDK2MKNK1 | |
| SCHEMBL5382444 | 0.90 | GSK3B (0.39) | GSK3BEIF2AK2MKNK1 | |
| SCHEMBL5378730 | 0.89 | MKNK1 (0.39) | GSK3BEIF2AK2MKNK1 | |
| SCHEMBL5379023 | 0.89 | MKNK1 (0.39) | GSK3BEIF2AK2MKNK1 | |
| SCHEMBL5388505 | 0.89 | SLC2A1 (0.48) | GSK3BEIF2AK2CDK2MKNK1CDK4 | |
| SCHEMBL5382297 | 0.89 | MAPK14 (0.46) | GSK3BEIF2AK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | GSK3B 326/4885EIF2AK2 1054/4885TRPA1 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.